spacer
home > ict > winter 2020 > comparator sourcing in china: three key trends for a new decade
PUBLICATIONS
International Clinical Trials

Comparator Sourcing in China: Three Key Trends for a New Decade




On average, more than 11,000 people are diagnosed with cancer in China every day. That is almost eight patients per minute. Dietary changes, smoking habits, and other lifestyle factors are also adding significant disease burdens. Although more Western lifestyles combined with better overall health has the positive effect of life expectancies improving, associated lifestyle illnesses – such as diabetes, stroke, and heart disease – are on the rise. In only a few decades, China has undergone substantial economic changes, but not without significant additional health and cost burdens.

The changing disease profiles, along with the rapid economic growth in China, pose a challenge for the healthcare system and has increased the demand for new and more complex treatments. Both global pharmaceutical companies and local manufacturers have caught up on this need, and one example of this is the large increase in the number of oncology trials being conducted in China.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer
About the author


Viktor Sandstedt is an Account Executive at Inceptua, where he coordinates and leads clinical trials supply sourcing projects for the Chinese market. With over eight years of experience in China, Viktor is an expert at bridging cultural gaps for western companies in China. During his time at Inceptua, Viktor has worked together with leading global pharma companies and small/midsize biotechs. His main focus is securing reliable supplies to ensure patients wellbeing is not put at risk. Viktor is fluent in Swedish, English, and Mandarin.
viktor.sandstedt@inceptua.com
Print this page
Send to a friend
Privacy statement
News and Press Releases

KKR Invests in Biosynth Carbosynth to Accelerate Growth and Help Build Global Life Sciences Tools Platform

London and Staad, 1 November 2021 – KKR, a leading global investment firm, and Biosynth Carbosynth, a leading life sciences reagents and custom synthesis and manufacturing services company, announce today that KKR has agreed to acquire Biosynth Carbosynth from Armira and CEO Dr. Urs Spitz. Dr. Spitz and senior managers of the company will retain a significant ownership stake and will continue to lead the company as it embarks on its next chapter of growth. Financial details of the transaction, which is subject to customary regulatory approvals, were not disclosed.
More info >>

White Papers

Tabletability, Compactability, and Compressibilty: What’s the Difference?

Natoli Engineering Company, Inc.

To patients and consumers, tablets are a simple and convenient dosage form. But the science behind compressing a block of particles or granules into a single tablet can be complicated. That’s where common compression studies can help. This article explains how to develop tabletability, compactibility, and compressibility profiles.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement